Business
Bloomberg reports Mylan chairman Robert Coury as telling investors he is prepared to reduce Perrigo shareholders' risk
Hi, what are you looking for?
Bloomberg reports Mylan chairman Robert Coury as telling investors he is prepared to reduce Perrigo shareholders' risk
Reuters Exclusive: Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to...
When Mylan and Perrigo executives had a “very preliminary” discussion a year ago about possibly merging the two generic drug companies, Perrigo was a...
John Paulson's hedge fund has increased its holdings in Mylan NV to 4.5%.
The Teva shareholder and digital printing pioneer thinks Teva should be investing in innovation, not cheap commodity drugs.
Mylan's filing on executive compensation reveals much higher pay than at Teva.
Mylan offered Perrigo shareholders $75 plus 2.3 Mylan shares per Perrigo share, for a total of $35.6 billion. Perrigo Company (NYSE:PRGO; TASE:PRGO) board of...
Mylan, itself the subject of a hostile takeover bid from Teva, is raising its offer for Perrigo for the second time. Mylan N.V. has...
Julius Baer analyst Lilian Montero insists it's illogical for Mylan to remain independent.
Teva CEO Erez Vigodman bypasses Mylan's board and appeals directly to its shareholders.